Immunoassay and complement diagnosticsprimary
2 projects
SciFiMed focuses on multiplex biosensors and complement diagnostics; RELENT addressed inflammatory signatures in autoimmune disease.
Organization
Hycult biotechnology bv
Dutch biotech SME developing immunoassays, complement diagnostics, and point-of-care biosensors for inflammation and immune disorder research.
Technology SMEhealthNLSME
H2020 projects
4
As coordinator
0
Total EC funding
€1.4M
Unique partners
52
What they do
Their core work
Hycult Biotechnology is a Dutch SME specializing in immunoassay development, antibody production, and diagnostic tools for inflammation and immune response research. They supply reagents and biosensor technologies used in clinical and preclinical studies of autoimmune disease, fungal infections, and gut-brain disorders. Their core commercial value lies in translating immunological research into diagnostic products — particularly complement system assays and multiplex biosensors that enable faster, more precise screening of inflammatory markers.
Core expertise
What they specialise in
Inflammation biomarker screeningprimary
3 projects
RELENT, DISCOvERIE, and SciFiMed all involve detection and characterization of inflammatory pathways and signatures.
Fungal immunology and host-directed therapysecondary
1 project
HDM-FUN targets host-directed medicine in invasive fungal infections including candidiasis and aspergillosis.
Gut-brain axis and comorbidity diagnosticsemerging
1 project
DISCOvERIE investigates somatic and mental comorbidities in irritable bowel syndrome, including brain-gut interaction.
Point-of-care diagnostic technologyemerging
1 project
SciFiMed explicitly targets point-of-care technology and liposome lysis assay for personalized inflammation screening.
Evolution & trajectory
How they've shifted over time
Early focus
Autoimmune inflammation pathways
Recent focus
Diagnostic biosensors and point-of-care
In their earlier H2020 work (2015–2020), Hycult focused on classical autoimmune disease mechanisms — relapse prevention, immunosenescence, and inflammatory regulatory pathways through the RELENT project. From 2020 onward, they shifted toward applied diagnostics and broader disease contexts: fungal infection immunology (HDM-FUN), gut-brain comorbidities (DISCOvERIE), and multiplex point-of-care biosensor development (SciFiMed). The trajectory is clear — moving from upstream immunological research toward diagnostic tool development and translational medicine applications.
Hycult is moving from being a reagent supplier in basic immunology research toward developing multiplex diagnostic platforms, making them increasingly relevant for clinical translation and personalized medicine consortia.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European17 countries collaborated
Hycult operates exclusively as a consortium participant, never as coordinator — typical for a specialized SME contributing specific technical capabilities rather than managing large projects. With 52 unique partners across 17 countries from just 4 projects, they join large, diverse consortia (averaging 13+ partners per project). This pattern suggests they are sought after for their niche diagnostic and immunoassay expertise rather than building their own research agenda.
Despite only 4 projects, Hycult has built a wide network of 52 partners across 17 countries, indicating they participate in large pan-European health consortia. Their reach spans well beyond the Netherlands, with no apparent geographic concentration.
Why partner with them
What sets them apart
Hycult occupies a specific niche as an SME that bridges immunological research and commercial diagnostic products. Unlike academic partners who contribute knowledge, or large diagnostics firms that contribute scale, Hycult brings specialized antibody and assay development capability at a size that allows genuine R&D engagement in consortium work. Their combination of complement system expertise, biosensor development, and commercial product pipeline makes them a practical partner for projects that need to move from biomarker discovery to a working diagnostic prototype.
Notable projects
Highlights from their portfolio
- RELENTLargest single grant (EUR 449,938) and their earliest H2020 project, establishing their position in autoimmune inflammation research.
- SciFiMedMost technology-forward project — developing multiplex biosensors and point-of-care diagnostics for personalized inflammation screening, signaling their commercial direction.
- HDM-FUNEUR 400,000 grant in the specialized field of host-directed therapy for invasive fungal infections, an area with few commercial players.
Cross-sector capabilities
Food safety and gut health diagnosticsVeterinary immunodiagnosticsEnvironmental biomonitoring via biosensorsPersonalized medicine and companion diagnostics
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →